Study Shows Prevalence of Lynch Syndrome in Solid Tumors Through MSI Status

Share this content:
The findings suggest that changes in genetic testing criteria are warranted.
The findings suggest that changes in genetic testing criteria are warranted.

The prevalence of Lynch syndrome patients with high frequency microsatellite instability (MSI-H) or mismatch repair deficiency (MMR-D) tumors was higher than anticipated in a clinical study, suggesting changes in genetic testing criteria are warranted.1 The findings were published in the Journal of Clinical Oncology.

Between 2014 and 2017, researchers enrolled 15,045 patients with more than 50 cancer types on a clinical trial at Memorial Sloan Kettering Cancer Center (ClinicalTrial.gov Identfier: NCT01775072). Targeted next-generation sequencing was used to identify MSI status for each patient. Patients' tumors were categorized as MSI-H, MSI-indeterminate, or microsatellite-stable. MMR-D was also assessed by immunohistochemical staining.

Continue Reading Below

Lynch syndrome was found in 16.3% of patients with MSI-H, 1.9% of patients with MSI-indeterminate, and 0.3% of patients with microsatellite-stable tumors (P < .001).

Half of Lynch syndrome patients with MSI-H or MSI-intermediate status tumors also had tumors that were not colorectal or endometrial; they included urothelial, prostate, pancreas, adrenocortical, small bowel, sarcoma, mesothelioma, melanoma, gastric, and germ cell tumors. Many of these patients (45%), however, did not meet the criteria that warrants genetic testing for Lynch syndrome. Nearly all patients (98.2%) with Lynch syndrome and MSI-H or MSI-intermediate tumors had mismatch repair deficiency (MMR-D).

“MSI-H/MMR-D is predictive of [Lynch syndrome] across a much broader tumor spectrum than currently appreciated,” the study authors concluded. “Given implications for cancer surveillance and prevention measures in affected families, these data support germline genetic assessment for LS for patients with an MSI-H/MMR-D tumor, regardless of cancer type or family cancer history.”

Reference

  1. Latham A, Srinivasan P, Kemel Y, et al. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer [published online October 30, 2018]. J Clin Oncol. doi: 10.1200/JCO.18.00283

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs